Tags

Type your tag names separated by a space and hit enter

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Arthritis Rheum 2008; 58(8):2453-9AR

Abstract

OBJECTIVE

To determine the association of plasma B lymphocyte stimulator (BLyS) levels, immunosuppressive therapy, and other clinical parameters with disease activity in systemic lupus erythematosus (SLE).

METHODS

Two hundred forty-five SLE patients were evaluated prospectively over a 2-year period at 4 centers. Assessments were performed every 3-6 months. Univariate analysis was used to determine the association among the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, serum anti-double-stranded DNA (anti-dsDNA), and plasma BLyS levels. A multivariate repeated-measures model incorporating immunosuppressive therapy was utilized.

RESULTS

Ninety-two percent of the patients were female. Sixty-seven percent were white, 31% African American, and 2% Asian (all of these groups may include Hispanic). Mean values at baseline were as follows: age 41.5 years, disease duration 8.1 years, SELENA-SLEDAI 3.3 (median 2, range 0-18), BLyS 5.57 ng/ml, IgG 1,439 mg/dl, C3 104.4 mg/dl, and C4 21.3 mg/dl; among those positive for anti-dsDNA, the median titer was 1:40 (range 1:10-1:1,280). Univariate analysis showed that plasma BLyS levels were associated with anti-dsDNA titers (P = 0.0465) and SELENA-SLEDAI scores (P = 0.0002). In multivariate analyses, a greater increase in the SELENA-SLEDAI score from the previous visit was associated with higher BLyS levels at the previous visit (P = 0.0042) and with a greater increase in the BLyS level from the previous visit (P = 0.0007).

CONCLUSION

The findings of association between a greater increase in the BLyS level from the previous visit and a greater increase in the SELENA-SLEDAI score at the subsequent visit, and between an elevated BLyS level at the previous visit and a greater SELENA-SLEDAI score at the subsequent visit, demonstrate a relationship between circulating BLyS levels and SLE disease activity. These results lend support to the notion that BLyS is a candidate for therapeutic targeting in SLE.

Authors+Show Affiliations

Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD 21205, USA. mpetri@jhmi.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

18668552

Citation

Petri, Michelle, et al. "Association of Plasma B Lymphocyte Stimulator Levels and Disease Activity in Systemic Lupus Erythematosus." Arthritis and Rheumatism, vol. 58, no. 8, 2008, pp. 2453-9.
Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453-9.
Petri, M., Stohl, W., Chatham, W., McCune, W. J., Chevrier, M., Ryel, J., ... Freimuth, W. (2008). Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis and Rheumatism, 58(8), pp. 2453-9. doi:10.1002/art.23678.
Petri M, et al. Association of Plasma B Lymphocyte Stimulator Levels and Disease Activity in Systemic Lupus Erythematosus. Arthritis Rheum. 2008;58(8):2453-9. PubMed PMID: 18668552.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. AU - Petri,Michelle, AU - Stohl,William, AU - Chatham,Winn, AU - McCune,W Joseph, AU - Chevrier,Marc, AU - Ryel,Jeff, AU - Recta,Virginia, AU - Zhong,John, AU - Freimuth,William, PY - 2008/8/1/pubmed PY - 2008/9/19/medline PY - 2008/8/1/entrez SP - 2453 EP - 9 JF - Arthritis and rheumatism JO - Arthritis Rheum. VL - 58 IS - 8 N2 - OBJECTIVE: To determine the association of plasma B lymphocyte stimulator (BLyS) levels, immunosuppressive therapy, and other clinical parameters with disease activity in systemic lupus erythematosus (SLE). METHODS: Two hundred forty-five SLE patients were evaluated prospectively over a 2-year period at 4 centers. Assessments were performed every 3-6 months. Univariate analysis was used to determine the association among the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, serum anti-double-stranded DNA (anti-dsDNA), and plasma BLyS levels. A multivariate repeated-measures model incorporating immunosuppressive therapy was utilized. RESULTS: Ninety-two percent of the patients were female. Sixty-seven percent were white, 31% African American, and 2% Asian (all of these groups may include Hispanic). Mean values at baseline were as follows: age 41.5 years, disease duration 8.1 years, SELENA-SLEDAI 3.3 (median 2, range 0-18), BLyS 5.57 ng/ml, IgG 1,439 mg/dl, C3 104.4 mg/dl, and C4 21.3 mg/dl; among those positive for anti-dsDNA, the median titer was 1:40 (range 1:10-1:1,280). Univariate analysis showed that plasma BLyS levels were associated with anti-dsDNA titers (P = 0.0465) and SELENA-SLEDAI scores (P = 0.0002). In multivariate analyses, a greater increase in the SELENA-SLEDAI score from the previous visit was associated with higher BLyS levels at the previous visit (P = 0.0042) and with a greater increase in the BLyS level from the previous visit (P = 0.0007). CONCLUSION: The findings of association between a greater increase in the BLyS level from the previous visit and a greater increase in the SELENA-SLEDAI score at the subsequent visit, and between an elevated BLyS level at the previous visit and a greater SELENA-SLEDAI score at the subsequent visit, demonstrate a relationship between circulating BLyS levels and SLE disease activity. These results lend support to the notion that BLyS is a candidate for therapeutic targeting in SLE. SN - 0004-3591 UR - https://www.unboundmedicine.com/medline/citation/18668552/Association_of_plasma_B_lymphocyte_stimulator_levels_and_disease_activity_in_systemic_lupus_erythematosus_ L2 - https://doi.org/10.1002/art.23678 DB - PRIME DP - Unbound Medicine ER -